Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 06/01/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Eaton Vance Worldwide Health Sciences Fund

EIHSX | Fund

$12.76

$763 M

0.83%

$0.11

0.96%

Vitals

YTD Return

-7.5%

1 yr return

4.0%

3 Yr Avg Return

3.3%

5 Yr Avg Return

3.5%

Net Assets

$763 M

Holdings in Top 10

55.7%

52 WEEK LOW AND HIGH

$13.0
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 0.96%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 32.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

$1,000,000

IRA

N/A

Fund Classification

Fund Type

Open End Mutual Fund

Name

As of 06/01/2026

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Eaton Vance Worldwide Health Sciences Fund

EIHSX | Fund

$12.76

$763 M

0.83%

$0.11

0.96%

EIHSX - Profile

Distributions

  • YTD Total Return -7.5%
  • 3 Yr Annualized Total Return 3.3%
  • 5 Yr Annualized Total Return 3.5%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.55%
DIVIDENDS
  • Dividend Yield 0.8%
  • Dividend Distribution Frequency None

Fund Details

  • Legal Name
    Eaton Vance Worldwide Health Sciences Fund
  • Fund Family Name
    EatonVance
  • Inception Date
    Oct 06, 2009
  • Shares Outstanding
    15236559
  • Share Class
    I
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Samantha Pandolfi

Fund Description

The Fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities (primarily common stocks) of companies principally engaged in the discovery, development, production or distribution of products (or services) related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies (“health sciences companies”) (the “80% Policy”). A company will be considered to be a health sciences company if, at the time of investment: (i) the company is classified as a member of the Global Industry Classification Standard (“GICS”) health care sector; (ii) the company is a component of the S&P 500 Health Care Index or the MSCI World Health Care Index; or (iii) 50% or more of the company’s sales, earnings or assets will arise from or will be dedicated to the application of scientific advances related to health care. The Fund invests in U.S. and foreign securities and will normally be invested in issuers located in and tied economically to at least three different countries. The Fund may invest in securities of both larger established and smaller emerging companies domiciled in developed or emerging markets, some of which may be denominated in foreign currencies or trade in the form of depositary receipts, such as American Depositary Receipts, which are either sponsored or unsponsored, and Global Depositary Receipts. The Fund has a policy of investing at least 25% of its assets in investments in the medical research and health care industry. Companies in the medical research and health care industry are categorized by GICS as pharmaceuticals, biotechnology, life sciences and health care equipment and services companies. The Fund may invest up to 5% of its total assets in royalty bonds, which are debt securities that are collateralized by royalties from pharmaceutical patents. The Fund may also invest in exchange-traded funds (“ETFs”), a type of pooled investment vehicle, in order to manage cash positions or seek exposure to certain markets or market sectors and may lend its securities.
The Fund may engage in derivative transactions to seek return, to hedge against fluctuations in securities prices or currency exchange rates, or as a substitute for the purchase or sale of securities or currencies. The Fund expects to use derivatives primarily to seek to generate income by writing covered call options or put options. The Fund may also enter into a combination of option transactions on individual securities. In addition, the Fund may seek to hedge against fluctuations in currency exchange rates through the use of forward foreign currency exchange contracts. Permitted derivatives include: the purchase or sale of forward or futures contracts; options on futures contracts; exchange-traded and over-the-counter options; equity collars and equity swap agreements. The Fund may also engage in covered short sales (on individual securities held or on an index or basket of securities whose constituents are held in whole or in part or for which liquid assets have been segregated). Except as required by applicable regulation, there is no stated limit on the Fund’s use of derivatives for such purposes.  
Investment decisions are made primarily on the basis of fundamental research. The portfolio managers seek to purchase stocks that are reasonably priced in relation to their fundamental value, and that they believe will grow in value over time regardless of short-term market fluctuations. In making investment decisions, the portfolio managers utilize the information provided by, and the expertise of, the investment adviser’s and sub-adviser’s research staff. In selecting stocks, the portfolio managers consider (among other factors) a company’s earnings or cash flow capabilities, dividend prospects, financial strength, growth potential, the strength of the company’s business franchises and management team, sustainability of a company’s competitiveness, estimates of the company’s net value, the potential to increase market share (for larger companies), and the potential of research and development projects (for smaller companies). The portfolio managers may consider selling a holding whenever there is a fundamental change to the investment thesis, the investment’s valuation target is reached, a security’s price falls below acquisition cost or to pursue more attractive investment opportunities. The portfolio managers seek to manage investment risk by maintaining issuer diversification among the Fund’s holdings, and by conducting an analysis of the risk and return characteristics of securities (as described above) in which the Fund invests.
Read More

EIHSX - Performance

Return Ranking - Trailing

Period EIHSX Return Category Return Low Category Return High Rank in Category (%)
YTD -7.5% -22.9% 20.0% 88.75%
1 Yr 4.0% -20.4% 134.5% 93.75%
3 Yr 3.3%* -6.3% 23.9% 79.38%
5 Yr 3.5%* -15.5% 12.3% 54.19%
10 Yr 7.0%* 3.0% 13.1% 72.44%

* Annualized

Return Ranking - Calendar

Period EIHSX Return Category Return Low Category Return High Rank in Category (%)
2025 2.9% -21.9% 61.0% 88.13%
2024 -0.9% -28.2% 19.2% 39.38%
2023 3.1% -8.6% 19.0% 47.50%
2022 -13.1% -53.9% 3.2% 58.06%
2021 12.6% -39.6% 24.2% 15.48%

Total Return Ranking - Trailing

Period EIHSX Return Category Return Low Category Return High Rank in Category (%)
YTD -7.5% -22.9% 20.0% 88.75%
1 Yr 4.0% -20.4% 134.5% 93.75%
3 Yr 3.3%* -6.3% 23.9% 79.38%
5 Yr 3.5%* -15.5% 12.3% 54.19%
10 Yr 7.0%* 3.0% 13.1% 72.44%

* Annualized

Total Return Ranking - Calendar

Period EIHSX Return Category Return Low Category Return High Rank in Category (%)
2025 10.6% -0.5% 63.7% 83.75%
2024 3.7% -28.2% 19.2% 36.88%
2023 6.0% -8.6% 19.0% 33.13%
2022 -9.2% -53.9% 3.7% 42.58%
2021 22.4% -33.9% 26.0% 6.45%

NAV & Total Return History

EIHSX - Holdings

Concentration Analysis

EIHSX Category Low Category High EIHSX % Rank
Net Assets 763 M 6.38 M 37.9 B 46.88%
Number of Holdings 44 24 416 90.00%
Net Assets in Top 10 478 M 3.49 M 22.8 B 41.88%
Weighting of Top 10 55.72% 16.2% 79.4% 15.63%

Top 10 Holdings

  1. Eli Lilly Co 11.33%
  2. AbbVie Inc 6.66%
  3. AstraZeneca PLC 6.54%
  4. Johnson Johnson 6.28%
  5. Roche Holding AG 5.85%
  6. Merck Co Inc 4.43%
  7. Bristol-Myers Squibb Co 4.10%
  8. UnitedHealth Group Inc 3.74%
  9. Vertex Pharmaceuticals Inc 3.51%
  10. Gilead Sciences Inc 3.27%

Asset Allocation

Weighting Return Low Return High EIHSX % Rank
Stocks 		99.67% 88.27% 106.13% 26.25%
Cash 		0.33% 0.00% 32.31% 85.00%
Preferred Stocks 		0.00% 0.00% 7.86% 90.00%
Other 		0.00% -22.99% 4.13% 82.50%
Convertible Bonds 		0.00% 0.00% 0.37% 86.45%
Bonds 		0.00% 0.00% 12.39% 87.50%

Stock Sector Breakdown

Weighting Return Low Return High EIHSX % Rank
Healthcare 		100.00% 59.26% 100.00% 38.71%
Utilities 		0.00% 0.00% 0.00% 84.52%
Technology 		0.00% 0.00% 22.69% 87.10%
Real Estate 		0.00% 0.00% 5.89% 85.81%
Industrials 		0.00% 0.00% 7.02% 85.81%
Financial Services 		0.00% 0.00% 1.60% 90.32%
Energy 		0.00% 0.00% 0.00% 84.52%
Communication Services 		0.00% 0.00% 9.11% 84.52%
Consumer Defense 		0.00% 0.00% 25.73% 86.45%
Consumer Cyclical 		0.00% 0.00% 1.92% 85.16%
Basic Materials 		0.00% 0.00% 7.16% 87.74%

Stock Geographic Breakdown

Weighting Return Low Return High EIHSX % Rank
US 		75.24% 60.50% 104.41% 94.38%
Non US 		24.43% 0.00% 36.86% 9.38%

EIHSX - Expenses

Operational Fees

EIHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.96% 0.08% 4.69% 60.63%
Management Fee 0.80% 0.03% 1.25% 67.50%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.15% 0.03% 0.25% 69.44%

Sales Fees

EIHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

EIHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

EIHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 32.00% 1.00% 238.00% 28.99%

EIHSX - Distributions

Dividend Yield Analysis

EIHSX Category Low Category High EIHSX % Rank
Dividend Yield 0.83% 0.00% 6.24% 13.75%

Dividend Distribution Analysis

EIHSX Category Low Category High Category Mod
Dividend Distribution Frequency None Annual Annual Annual

Net Income Ratio Analysis

EIHSX Category Low Category High EIHSX % Rank
Net Income Ratio 0.55% -2.54% 1.85% 14.38%

Capital Gain Distribution Analysis

EIHSX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

EIHSX - Fund Manager Analysis

Managers

Samantha Pandolfi

Start Date

Tenure

Tenure Rank

Jul 01, 2016

5.92

5.9%

Ms. Pandolfi is a Vice President of EVAIL. Prior to joining EVAIL, Ms. Pandolfi held similar positions at EVMI. Prior to joining EVMI as a Vice President in November 2015, Ms. Pandolfi was a Portfolio Manager and Research Analyst with Goldman Sachs Asset Management over her fifteen year tenure (2000-2015).

Jason Kritzer

Start Date

Tenure

Tenure Rank

Jul 01, 2016

5.92

5.9%

Mr. Kritzer is a Vice President of Eaton Vance. Prior to joining Eaton Vance in 2012, Mr. Kritzer was a director and equity analyst at BlackRock , Inc. covering the healthcare sector since 2006.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 8.08 0.25

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.